Goldman Sachs
RUBY

Goldman Sachs’s Rubius Therapeutics, Inc RUBY Stock Holding History

Goldman Sachs’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$290K – 7077
2021
Q4 		$290K Hold
30,000
– – ﹤0.01% 5688
2021
Q3 		$536K Buy
+30,000
New +$653K ﹤0.01% 5151

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Goldman Sachs's RUBY Position: Q1 2023 in Review

Goldman Sachs sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 17,511 shares — an estimated $3.06K sold.

Goldman Sachs first reported a position in RUBY in Q4 2018 and held it in 17 quarters. The position peaked at $6.66M in Q3 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Goldman Sachs reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 17,511 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $3.06K.
  • Goldman Sachs first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 17 quarters.
  • Goldman Sachs's Rubius Therapeutics, Inc position peaked at $6.66M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.